Weighted Average Cost of Capital (WACC)

搜索文档
Delcath Systems, Inc. (NASDAQ:DCTH) Financial Performance and Competitive Landscape
Financial Modeling Prep· 2025-09-16 08:00
公司业务与行业定位 - 公司专注于肿瘤学领域 开发治疗原发性和转移性肝癌的疗法 [1] - 核心产品为肝脏输送系统 可实现肝脏高剂量化疗并最小化全身暴露 [1] - 主要竞争对手包括Interpace Biosciences、EOM Pharmaceuticals Holdings、Aeterna Zentaris及Rennova Health [1] 资本效率表现 - 公司ROIC为3.58% 低于WACC的7.61% 显示资本回报未能覆盖资本成本 [2] - Interpace Biosciences的ROIC达84.16% 显著高于其9.41%的WACC ROIC/WACC比率达8.94 [3] - EOM Pharmaceuticals Holdings的ROIC高达1,140.12% 远超其16.82%的WACC ROIC/WACC比率达67.77 [4] - Aeterna Zentaris与Rennova Health的ROIC均为负值 反映资本回报能力存在结构性挑战 [4]
Nu Holdings Ltd. (NYSE:NU) Financial Efficiency Analysis
Financial Modeling Prep· 2025-09-15 23:00
公司业务与竞争格局 - Nu Holdings Ltd 是拉丁美洲领先的数字银行平台 提供信用卡、个人贷款和储蓄账户等金融服务[1] - 公司采用创新银行模式 利用技术提供普惠金融解决方案[1] - 主要竞争对手包括 StoneCo Ltd、SoFi Technologies、Grab Holdings Limited、Affirm Holdings 和 Toast Inc[1] 财务效率分析 - Nu Holdings 的投入资本回报率(ROIC)为5.51% 低于其加权平均资本成本(WACC)11.72%[2][6] - ROIC与WACC比率为0.47 表明公司未能产生超过资本成本的回报[2] - 这种状况可能影响股东价值创造 需要提升运营效率或成本管理能力[2] 同业比较 - StoneCo Ltd 表现突出 ROIC达38.70% WACC为11.08% 比率高达3.49[3] - SoFi Technologies ROIC为4.93% 低于WACC的14.69% 比率为0.34[4] - Grab Holdings ROIC为-0.11% WACC为7.68% 比率为-0.01[5] - Affirm Holdings ROIC为-0.66% WACC为17.45% 比率为-0.04[5] - 多数同业公司都面临ROIC低于WACC的挑战 仅StoneCo实现显著超额回报[6]
Understanding Capital Efficiency in the Digital Financial Services Sector
Financial Modeling Prep· 2025-09-15 08:00
公司财务表现 - Remitly Global的ROIC为2.09% WACC为4.64% ROIC与WACC比率为0.45 显示公司未能实现超过资本成本的回报 [2] - 与同业相比 Sterling Check Corp的ROIC为1.89% WACC为6.10% 比率0.31 在同行中资本使用效率最高 [3][4] - Expensify的ROIC为1.09% WACC为12.06% 比率0.09 同样未能产生超过资本成本的回报 [3] 同业比较分析 - AvidXchange Holdings的ROIC为-2.62% WACC为9.49% 比率为-0.28 显示资本使用效率极低 [2] - Flywire Corporation的ROIC为-0.77% WACC为9.76% 比率为-0.08 Blend Labs的ROIC为-20.91% WACC为10.11% 比率为-2.07 两者均存在显著的资本回报低效问题 [4] - 数字金融服务行业面临普遍挑战 多数同业公司未能实现ROIC超过WACC [2][3][4] 行业竞争格局 - 公司专注于国际汇款业务 在数字支付和汇款领域与金融科技公司存在竞争 [1] - 行业参与者包括AvidXchange Holdings、Expensify、Sterling Check Corp、Flywire Corporation和Blend Labs等多家企业 [2][3][4]
Emerald Holding, Inc. (NYSE:EEX) Financial Performance and Competitive Analysis
Financial Modeling Prep· 2025-09-15 08:00
Emerald Holding, Inc. (NYSE:EEX) has a Return on Invested Capital (ROIC) of 2.91%, which is lower than its Weighted Average Cost of Capital (WACC) of 9.06%, indicating inefficiency in generating sufficient returns on investments.Comparative analysis shows that peers like Byline Bancorp, Inc. and WideOpenWest, Inc. also struggle with their ROIC to WACC ratios, whereas Hamilton Beach Brands Holding Company and Clipper Realty Inc. demonstrate more efficient capital utilization.Clipper Realty Inc. stands out wi ...
Excelerate Energy's Financial Performance in the Competitive LNG Market
Financial Modeling Prep· 2025-09-14 23:00
公司业务与行业定位 - Excelerate Energy专注于液化天然气解决方案 在公用事业领域与PNM Resources IDACORP Black Hills Corporation Avista Corporation及Southwest Gas Holdings等企业存在竞争关系[1] - 公司所处的公用事业领域具有稳定但竞争激烈的行业特征[1] 财务表现分析 - 公司投入资本回报率为5.21% 低于7.17%的加权平均资本成本 显示资本使用效率未达理想状态[2] - ROIC与WACC比值为0.73 虽未达行业最优水平 但优于部分同业公司[4][5] 同业比较情况 - Black Hills Corporation资本效率最高 ROIC达4.87% WACC为5.40% ROIC/WACC比值为0.90[3] - PNM Resources出现严重资本效率问题 ROIC为-122.19% 远低于其4.24%的WACC ROIC/WACC比值低至-28.82[3] - IDACORP的ROIC/WACC比值为0.65 Avista为0.81 Southwest Gas Holdings为0.59 均低于Excelerate Energy的0.73[4]
Chemung Financial Corporation's Capital Utilization Analysis
Financial Modeling Prep· 2025-09-14 08:00
Chemung Financial Corporation (NASDAQ:CHMG) struggles with capital utilization, having a negative ROIC to WACC ratio.Investar Holding Corporation showcases exceptional efficiency with a high ROIC to WACC ratio, indicating superior capital utilization.Comparative analysis with peers reveals varying efficiencies in capital utilization across the banking sector.Chemung Financial Corporation (NASDAQ:CHMG) is a regional bank holding company based in New York. It provides a range of financial services, including ...
DoubleDown Interactive's Capital Efficiency Outshines Peers
Financial Modeling Prep· 2025-09-14 08:00
DoubleDown Interactive Co., Ltd. (NASDAQ:DDI) showcases a ROIC of 10.23%, significantly surpassing its WACC of 7.69%.Bragg Gaming Group Inc. and Integral Ad Science Holding Corp. struggle with negative ROICs, indicating inefficiencies in capital utilization.DoubleDown Interactive's superior ROIC to WACC ratio of 1.33 highlights its effective management and value creation for investors.DoubleDown Interactive Co., Ltd. (NASDAQ:DDI) is a prominent player in the digital gaming industry, known for its engaging s ...
Nektar Therapeutics' Financial Performance Raises Concerns
Financial Modeling Prep· 2025-09-14 08:00
公司核心财务表现 - Nektar Therapeutics的投入资本回报率为-63.50%,远低于其11.16%的加权平均资本成本,表明资本使用效率低下[2][6] - Alkermes plc的投入资本回报率为18.03%,显著高于其6.18%的加权平均资本成本,资本利用率高[3][6] - Sangamo Therapeutics的投入资本回报率为-125.56%,远低于其8.02%的加权平均资本成本,面临与Nektar类似的资本使用效率挑战[5][6] 同业公司比较 - Neurocrine Biosciences的投入资本回报率与加权平均资本成本之比为1.78,表明其回报超过资本成本[4] - Incyte Corporation的投入资本回报率与加权平均资本成本之比为2.50,同样产生高于资本成本的回报[4] - Alkermes plc的投入资本回报率与加权平均资本成本之比为2.92,在同业比较中表现最为强劲[3]
Bridgeline Digital, Inc. (NASDAQ:BLIN) Financial Performance Analysis
Financial Modeling Prep· 2025-09-13 23:00
Bridgeline Digital's ROIC is -21.51%, indicating it is not generating sufficient returns to cover its WACC of 7.83%.Despite a negative ROIC, BLIN's capital efficiency is relatively better than peers like Marin Software and Verb Technology.Carver Bancorp and NeuroMetrix also struggle with capital efficiency, but BLIN shows better management in utilizing its capital compared to most of its peers.Bridgeline Digital, Inc. (NASDAQ:BLIN) is a company that provides digital engagement solutions. It offers a suite o ...
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Financial Performance Analysis
Financial Modeling Prep· 2025-09-13 23:00
Akebia Therapeutics, Inc. (NASDAQ:AKBA) has a Return on Invested Capital (ROIC) of 0.34% and a Weighted Average Cost of Capital (WACC) of 10.46%, indicating inefficiencies in capital utilization.Ardelyx, Inc. (NASDAQ:ARDX) shows a slightly better ROIC to WACC ratio compared to its peers, despite it being negative.FibroGen, Inc. (NASDAQ:FGEN), Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Calithera Biosciences, Inc. (NASDAQ:CALA), and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) face significant challenges in gene ...